www.fdanews.com/articles/134147-targacept-begins-phase-ii-studies-of-tc-6987-in-asthma-and-type-2-diabetes

Targacept Begins Phase II Studies of TC-6987 in Asthma and Type 2 Diabetes

February 9, 2011

Targacept, Inc. Wednesday announced the initiation of separate Phase II clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
StreetInsider